

13 June 2018

ASX Announcements Office
152–158 St Georges Terrace
Perth WA 6000
Australia

Appendix 3B – Securities Exercised

Force Commodities Ltd (**Force** or the **Company**) (ASX Code: 4CE) is pleased to confirm that it has completed the issue of the following securities:

1. 2,000,000 fully paid ordinary shares (Shares) in the capital of the Company pursuant to the terms of a Joint Venture and Development Agreement with Kanuka Mining Company SARL and in respect of the Kanuka Lithium Production Project;
2. 2,500,000 options to Mr Gedeon Pelesa, exercisable at \$0.10 (i.e. 10 cents) on or before 5pm on 30 June 2020, as approved by shareholders at the Company's Annual General Meeting of 25 May 2018; and
3. 1,800,000 Performance Rights to Mr Jason Brewer, as approved by shareholders at the Company's Annual General Meeting of 25 May 2018.

An Appendix 3B in relation to the above issued securities is attached.



MICHAEL FRY
COMPANY SECRETARY
FORCE COMMODITIES LIMITED

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

FORCE COMMODITIES LIMITED

ABN

12 145 184 667

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | 1 | +Class of +securities issued or to be issued | <ul style="list-style-type: none"> (i) Fully paid ordinary shares (FPO Shares) (ii) Unlisted Options (iii) Performance Rights | | | | | | | | |
|---------|---|--|--------|--------------|---------|------------------|---------|------------------|---------|------------------|
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | <ul style="list-style-type: none"> (i) 2,000,000 FPO Shares to vendor of Kanuka Lithium Production Project (ii) 2,500,000 Unlisted Options (iii) 1,800,000 Performance Rights | | | | | | | | |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <ul style="list-style-type: none"> (i) FPO Shares (ii) Unlisted Options are exercisable on or before 30 June 2020 at an exercise price of \$0.10 (iii) Performance Rights vest into FPO Shares as follows: <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <thead> <tr> <th style="width: 50%;">Number</th> <th style="width: 50%;">Vesting date</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">600,000</td> <td style="text-align: center;">19 February 2019</td> </tr> <tr> <td style="text-align: center;">600,000</td> <td style="text-align: center;">19 February 2020</td> </tr> <tr> <td style="text-align: center;">600,000</td> <td style="text-align: center;">19 February 2021</td> </tr> </tbody> </table> <p>Each Performance Right converts into One FPO Share provided that the recipient remains in employment with the Company on the Vesting Date.</p> | Number | Vesting date | 600,000 | 19 February 2019 | 600,000 | 19 February 2020 | 600,000 | 19 February 2021 |
| Number | Vesting date | | | | | | | | | |
| 600,000 | 19 February 2019 | | | | | | | | | |
| 600,000 | 19 February 2020 | | | | | | | | | |
| 600,000 | 19 February 2021 | | | | | | | | | |

4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	(i) Yes (ii) Yes, upon conversion (iii) Yes, upon conversion
	If the additional +securities do not rank equally, please state: <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	(i) Nil (ii) Nil (iii) Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets).	(i) Issue of shares to vendors of Kanuka Lithium production Project; (ii) Pursuant to employment arrangement for non-executive director; and (iii) Pursuant to Managing Director's employment agreement.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	(i) Yes (ii) Yes (iii) Yes
	If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	25 May 2018
6c	Number of +securities issued without security holder approval under rule 7.1	(i) 2,000,000 FPO Shares (ii) Nil (iii) Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil

+ See chapter 19 for defined terms.

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	(i) Nil (ii) 2,500,000 Unlisted Options (iii) 1,800,000 Performance Rights Date of Meeting: 25 May 2018				
6f	Number of +securities issued under an exception in rule 7.2	N/a				
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/a				
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/a				
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1: 60,987,380 Rule 7.1A: 41,991,586				
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	13 June 2018				
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="766 1404 1069 1451">Number</th> <th data-bbox="1069 1404 1359 1451">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="766 1451 1069 1666">421,915,868</td> <td data-bbox="1069 1451 1359 1666">FPO Shares</td> </tr> </tbody> </table>	Number	+Class	421,915,868	FPO Shares
Number	+Class					
421,915,868	FPO Shares					

9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	Number	+Class							
		26,416,662	Unlisted Options (exercisable at \$0.032 expiring 30 June 2019)							
		10,000,000	Unlisted Options (exercisable at \$0.035 expiring 30 June 2019)							
		937,500	Unlisted Options (exercisable at \$0.048 expiring 5 August 2019)							
		2,000,000	Unlisted Options (exercisable at \$0.06 expiring 1 July 2020)							
		2,000,000	Unlisted Options (exercisable at \$0.08 expiring 1 July 2020)							
		2,500,000	Unlisted Options (exercisable at \$0.10 expiring 30 June 2020)							
	1,800,000	Performance Rights vesting as follows:								
		<table border="1"> <thead> <tr> <th>Number</th> <th>Vesting date</th> </tr> </thead> <tbody> <tr> <td>600,000</td> <td>19 Feb 2019</td> </tr> <tr> <td>600,000</td> <td>19 Feb 2020</td> </tr> <tr> <td>600,000</td> <td>19 Feb 2021</td> </tr> </tbody> </table>	Number	Vesting date	600,000	19 Feb 2019	600,000	19 Feb 2020	600,000	19 Feb 2021
Number	Vesting date									
600,000	19 Feb 2019									
600,000	19 Feb 2020									
600,000	19 Feb 2021									
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable								

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	Not applicable
13	Ratio in which the +securities will be offered	Not applicable
14	+Class of +securities to which the offer relates	Not applicable

+ See chapter 19 for defined terms.

15	+Record date to determine entitlements	Not applicable
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	<p>Names of countries in which the entity has security holders who will not be sent new offer documents</p> <p>Note: Security holders must be told how their entitlements are to be dealt with.</p> <p>Cross reference: rule 7.7.</p>	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable

+ See chapter 19 for defined terms.

20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable

+ See chapter 19 for defined terms.

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 +Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities
(tick one)

(a) +Securities described in Part 1

(b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought	Not applicable	
39	+Class of +securities for which quotation is sought	Not applicable	
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <p>(a) the date from which they do</p> <p>(b) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</p> <p>(c) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</p>	Not applicable	
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>	Not applicable	
42	<p>Number and +class of all +securities quoted on ASX (including the +securities in clause 38)</p>	Number	+Class

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:
(Company secretary)

Date: 13 June 2018

Print name: MICHAEL FRY

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	214,957,538
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>53,666,666 issued in a placement to sophisticated investors on 24 July 2017</p> <p>2,750,000 issued to consultants in lieu of cash payment on 14 November 2017</p> <p>1,833,333 issued on exercise of options on 20 November 2017</p> <p>250,000 issued on exercise of options on 24 November 2017</p> <p>5,562,500 issued on exercise of options on 11 December 2017</p> <p>1,333,332 issued on exercise of options on 18 December 2017</p> <p>32,929,246 issued to sophisticated and professional investors pursuant to December 2017 Placement</p> <p>27,070,754 issued to sophisticated and professional investors pursuant to December 2017 Placement</p> <p>7,541,666 issued on exercise of options on 16 January 2018</p> <p>2,520,833 issued on exercise of options on 22 January 2018</p> <p>67,500,000 issued in consideration for acquisition of 70% interest in Kitotolo Lithium Project on 14 February 2018</p> <p>1,000,000 issued on exercise of options on 14 February 2018</p>
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	
“A”	419,915,868

+ See chapter 19 for defined terms.

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	62,987,380
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	2,000,000 issued to vendor of Kanuka Lithium Production Project
“C”	2,000,000
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	62,987,380
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	2,000,000
Total [“A” x 0.15] – “C”	60,987,380 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	419,915,868
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	41,991,586
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
“E”	-

+ See chapter 19 for defined terms.

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	42,191,586
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	-
Total [“A” x 0.10] – “E”	42,191,586 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.

+ See chapter 19 for defined terms.